Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statement of Stockholders' Equity

v3.24.1.u1
Consolidated Statement of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2022   78,745      
Balance at beginning of period at Dec. 31, 2022 $ 676,385 $ 8 $ 722,778 $ (1,021) $ (45,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued pursuant to equity awards, net (in shares)   1,236      
Common stock issued pursuant to equity awards, net 31,926   31,926    
Stock-based compensation 16,460   16,460    
Other comprehensive loss (192)     (192)  
Net income (loss) 9,533       9,533
Balance at end of period (in shares) at Mar. 31, 2023   79,981      
Balance at end of period at Mar. 31, 2023 $ 734,112 $ 8 771,164 (1,213) (35,847)
Balance at beginning of period (in shares) at Dec. 31, 2023 81,818 81,818      
Balance at beginning of period at Dec. 31, 2023 $ 686,265 $ 8 808,575 (3,791) (118,527)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Common stock issued pursuant to equity awards, net (in shares)   1,249      
Common stock issued pursuant to equity awards, net 8,777   8,777    
Stock-based compensation 17,032   17,032    
Other comprehensive loss (1,782)     (1,782)  
Net income (loss) $ (72,309)       (72,309)
Balance at end of period (in shares) at Mar. 31, 2024 83,067 83,067      
Balance at end of period at Mar. 31, 2024 $ 637,983 $ 8 $ 834,384 $ (5,573) $ (190,836)